Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?
McLeod
H L
HL
CRC Department of Medical Oncology, University of Glasgow, Bearsden, U.K.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D006801:Humans; D010641:Phenotype
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D016572:Cyclosporine